Across TCGA pan-cancer cohorts, DDX41 Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated DDX41 data layer compared with 24 for mass-spec protein and 5 for mass-spec protein.
The strongest signal is observed in stomach adenocarcinoma (STAD), where higher DDX41 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated DDX41 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
STAD, COAD, and BRCA are the cancer types where DDX41 Mutation most reproducibly stratifies survival.